Close
Nordic 9Nordic 9

Glenview Capital Management (investor - Private Equity)

United States
See something wrong or missing? Let us know
Offices:New York

Glenview Capital Management is an American hedge fund

Average round investment:60M USD
Average number per year:1.0
Distribution: 2024 (1)
Portfolio companies: United Kingdom Quanta Dialysis Technologies
Mostly invests in: United Kingdom United Kingdom (1) Biotech (1)

1 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Glenview Capital Management

Name Criteria
United Kingdom Abingworth
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Intuitive Ventures
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Alex Gorsky
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Belgium Merifin Capital
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Brace Pharma Capital
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States venBio Partners
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
United States Research Corporation Technologies
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
United States Redmile Group
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
United States MRL Ventures
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
Switzerland Korify Capital
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
Top